SAFC recently added two new CompoZrR Zinc Finger Nucleases (ZFN) as off-the-shelf catalog items to modify CHO cells for biopharmaceutical production. The two new ZFNs will knock out dhfr and GS genes - both of which are useful in selection of recombinant clones of interest. This catalog offer is in addition to services to create custom ZFN products for other genes of interest or custom cell engineering services (CCES) to create modified cell lines.
The offer is intended to enable biopharmaceutical customers to create robust, efficient cell lines, thus allowing them to focus their R&D efforts on developing new therapeutics. The ability to make targeted, heritable changes to genes has already lead to quicker development of knock-out cell lines for biopharm production.
This is an evolving offer at SAFC. The company plans to add new ZFNs targetted to different genes on a regular basis affecting properties like cell production, cell growth, culture longevity, recombinant protein quality (glycosylation), elimination of HCPs or viral elments, etc. Modified CHO K1 clones will also be offered as catalog items soon. The first cell lines will be biallelic knockouts of dhfr and GS with others soon to follow. It is SAFC's intention to offer a CHO cell line platform with optimized chemically-defined medium and feed sets, process instructions and complete validation and application package to support the production of therapeutics. We believe that this wil be interesting to biopharmaceutical, vaccine and biosimilar producers.
Posted by Bruce Lehr December 21st 2010.